医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Award-Winning Data CRO Expands Executive Leadership to Support Company’s Next Stage of Growth

2023年02月07日 PM11:01
このエントリーをはてなブックマークに追加


 

CANTON, Mich.

MMS Holdings (MMS) – an award-winning, data-focused contract research organization (CRO) – announces the expansion of its leadership team with the appointment of Chris Schoonmaker as Chief Operating Officer and Ashu Tandon as Chief Commercial Officer. This comes as the company was recognized in the 2023 Top Workplace USA awards, a national list of organizations with strong company cultures and high employee satisfaction rates, and a Great Place to Work in India.

Both Schoonmaker and Tandon have decades of experience in the pharmaceutical and healthcare industry and have held leadership positions at other CROs.

“We are excited to welcome Chris and Ashu to the #OneMMS team,” said Dr. Uma Sharma, Chief Executive Officer, MMS. “I look forward to their leadership and strength for our continued growth as we scale our teams and clients globally to be the best in business.”

MMS Growth

The expansion of the MMS executive leadership team, including the newly created position of Chief Commercial Officer, will allow the company to continue growing its teams and services across its global operations.

“I’m excited to join and help expand MMS’ reach as we continue to bring value to Sponsors by helping them bring new therapies to market,” said Tandon, CCO, MMS. “We have strong expertise across our many services, and I look forward to connecting Sponsors with the MMS services that are the right fit for their needs.”

Enhancing the MMS Mission

MMS has maintained one of the highest retention rates in the pharma industry and a positive colleague culture since its inception. These aspects of MMS enhance its mission of delivering high-quality service and technology solutions to assist clients in developing life-changing therapies.

Recently, MMS was recognized for its great company culture by the Top Workplaces USA awards for the second consecutive year. The winners of this award are chosen based solely on employee feedback gathered through an employee engagement survey.

“I’m grateful to work at a company with such a strong company culture that cares about its colleagues,” said Schoonmaker, COO, MMS. “Being a part of growing the company and developing the business strategies and operational excellence needed to continue our success is exciting and rewarding to me after many years in this space.”

About MMS

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005304/en/

CONTACT

Avery Zimmerman

media@mmsholdings.com

同じカテゴリーの記事 

  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report